https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/seek_media_content_6b2d9291fffba185fd255dda28ed2961.html ...

Novartis Third Quarter and Nine Months 2023 Condensed Interim Financial Report – Supplementary Data INDEX Page COMPANY OPERATING PERFORMANCE REVIEW Continuing operations 3 Discontinued operations 11 Total Company 11 COMPANY CASH FLOW AND BALANCE SHEET 12 INNOVATION REVIEW 16 CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS Consolidated income statements 19 Consolidated statements of comprehensive income 21 Consolidated balance sheets 22 Consolidated statements of changes in equity 23 Consolidated stateme ...

Novartis AG (NYSE:NVS) Q2 2023 Earnings Conference Call July 18, 2023 8:00 AM ET Company Participants | --- | --- | |------------------------------------------------------------------------------------------------------------------------------|-------| | | | | Samir Shah - Global Head, Investor Relations Vas Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer | | | Conference Call Participants | | | Richard Vosser - JPMorgan | | | Jo Walton - Credit Suisse | | | Emmanuel Papadakis - ...

Novartis Second Quarter and Half Year 2023 Condensed Interim Financial Report – Supplementary Data INDEX Page GROUP AND DIVISIONAL OPERATING PERFORMANCE Group 3 Innovative Medicines 7 Sandoz 13 CASH FLOW AND GROUP BALANCE SHEET 15 INNOVATION REVIEW 18 CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS Consolidated income statements 21 Consolidated statements of comprehensive income 23 Consolidated balance sheets 24 Consolidated statements of changes in equity 25 Consolidated statements of cash flows 27 Not ...

Andrew Baum Thank you. Please forgive the voice. I'm struggling with COVID. A question for Vas, I suspect you remember, historically, I've described the bases is suffering from [indiscernible] syndrome in always being the early adopter and taking unnecessary risk relative to peers. IÂ'm going to completely contradict myself. The early data from SET with RT CD19 in refractory autoimmune is remarkable. The biology is strong, patient access node patients is much easier in oncology. We understand that Bristol i ...

eBC – early breast cancer. ET – endocrine therapy. iDFS – invasive disease-free survival. 1. Unprobabilized peak sales. 2. Under stage II: N0, T0N1 is excluded; T2N0 only if G3, or G2 with Ki67≥20% or high risk on Oncotype DX / Prosigna / MammaPrint / EndoPredict. 3. Estimated incidence US + EU5. Sources: DRG (US) and Kantar (EU5). TNM and grade information based on SEER AJCC 8th Incidence Report. 9 NOVARTIS Q1 RESULTS | APRIL 25, 2023 | NOVARTIS INVESTOR PRESENTATION APPOINT-PNH: Single-arm Ph3 trial in ad ...

Novartis AG (NYSE:NVS) Q4 2022 Earnings Conference Call February 1, 2023 8:00 AM ET Company Participants Samir Shah - Global Head of Investor Relations Vasant Narasimhan - Chief Executive Officer Harry Kirsch - Chief Financial Officer Conference Call Participants Matthew Weston - Credit Suisse Graham Parry - Bank of America Stephen Scala - Cowen Tim Anderson - Wolfe Research Florent Cespedes - Société Générale Peter Welford - Jefferies Seamus Fernandez - Guggenheim Securities Andrew Baum - Citi Keyur Parekh ...

INNOVATION Improvements across a range of other secondary endpoints: Increasing Hb, reducing patient-reported fatigue and reticulocyte count, maintaining low LDH Duration Company overview Financial review 2023 priorities Appendix Iptacopan 200mg BID1 Met primary endpoint of proportion of patients achieving a sustained increase in Hb of ≥ 2g/dL, in the absence of transfusions, at 24 weeks ... and showed clinically meaningful increases in Hb levels for treatment-naive adult patients with PNH Company overview ...

As filed with the Securities and Exchange Commission on February 1, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Form 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 for the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☐ SHELL COMPANY REPORT PURSU ...

Novartis(NVS) - 2022 Q4 - Annual Report ...